Content about Abraxis

LOS ANGELES Abraxis BioScience shareholders have approved an acquisition of the company by Celgene, Celgene said Wednesday.

The $3 billion acquisition will give Celgene control of Abraxis’ cancer therapies and its anti-tumor Nab technology.